CJ Bioscience to launch microbiome analysis service in 2024

The company plans to officially introduce the microbial life information analysis app EzBiome Bioinformatics

CEO of CJ Bioscience Chun Jong-Sik (right) speaks at the company's workshop 
CEO of CJ Bioscience Chun Jong-Sik (right) speaks at the company's workshop 
Ye-Na Kim 1
2023-07-28 16:05:05 yena@hankyung.com
Bio & Pharma

South Korea's CJ Bioscience Inc. announced on Friday that it plans to officially launch the microbe analysis platform "EzBiome Bioinformatics app" (EzBiome) next year.

EzBiome is a software-as-a-service (SaaS) microbial life information analysis platform. The company explained that it rapidly analyzes microbiome-related data to generate results that can be used in clinical trials and other applications.

Starting this month, the company is conducting a pilot service by opening some features to industry professionals and academic researchers, incorporating expert feedback before the official launch. It is also considering adopting artificial intelligence (AI) to analyze microbiome genomes. The company held a workshop on July 26 for industry professionals on the functionalities and applications of EzBiome.

"With the recent expansion of genome analysis services in hospitals and other facilities, the demand in the clinical and infectious disease diagnosis fields is growing, and the related market is expected to continue to grow," a CJ Bioscience source said. "We plan to provide a premium service based on world-class microbiome data analysis technology,"

The microbiome is a term that combines microorganisms and ecosystems, referring to the tens of trillions of microorganisms and their genes that exist in the human body. Among them, beneficial species are being utilized in pharmaceuticals and health-functional foods.

Write to Ye-Na Kim at yena@hankyung.com

CJ Bioscience conducts paid-in capital increase of $50 mn

CJ Bioscience conducts paid-in capital increase of $50 mn

South Korea's CJ Bioscience Inc., a pharmaceutical company specializing in intestinal microorganisms called microbiomes, will conduct a paid-in capital increase of 65 billion won ($49.2 million) to develop new drugs. CEO Chun Jong-sik is also participating in this to raise funds for R&D in

Korea's CJ Bioscience buys drug candidates from 4D pharma of the UK

Korea's CJ Bioscience buys drug candidates from 4D pharma of the UK

(Captured from 4D pharma website) South Korea’s pharmaceutical and healthcare company CJ Bioscience Inc. has acquired drug candidates from the UK's 4D pharma plc. to improve competitiveness in the development of new medicine.The subsidiary of South Korea’s food and bio giant CJ Chei

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 and 2 clinical trial protocol for CJRB-101, an immuno-anticancer drug candidate, to the US Food and Drug Administration (FDA). CJRB-101 is a

(* comment hide *}